Expressing support for the designation of July 15, 2026, as "Glioblastoma Awareness Day".

Bill Summary: H.Res. 1270 (119th Congress)

Purpose

• Expresses support for designating July 15, 2026, as “Glioblastoma Awareness Day.”
• Aims to raise public awareness about glioblastoma, its prognosis, and the ongoing need for research and improved treatments.

Key Provisions and Provisions Details

• Statement of support:
  • The House of Representatives expresses support for designating July 15, 2026, as Glioblastoma Awareness Day.
• Public awareness and recognition:
  • Encourages increased public awareness of glioblastoma.
  • Honors individuals who have died from glioblastoma or are currently living with the disease.
• Support for research and treatment:
  • Supports efforts to develop better treatments to improve long-term prognosis and quality of life for those diagnosed.
  • Recognizes the importance of molecular biomarker testing in diagnosis and treatment.
  • Encourages collaboration among governmental, private, and nonprofit organizations to advance brain tumor research.
  • Encourages continued investments in glioblastoma research and treatments, including through the Glioblastoma Therapeutics Network (GTN) and other brain tumor resources.
• Human impact and support networks:
  • Expresses support for individuals battling brain tumors and for their families, friends, and caregivers.
• Legislative stance:
  • Emphasizes a collaborative approach and ongoing investment in glioblastoma research as a policy priority.

Who/What Is Affected

• Affects: House adoption and public commemoration practices, as the resolution functions as an expression of Congress.
• Stakeholders highlighted:
  • Glioblastoma patients and survivors
  • Families, caregivers, and friends of those affected
  • Researchers and institutions involved in glioblastoma and brain tumor research
  • Agencies and organizations participating in the Glioblastoma Therapeutics Network and related efforts

Procedural and Timeline Aspects

• Introduction date: May 7, 2026.
• Referred to the House Committee on Energy and Commerce (no further action listed in the provided text).
• No substantive budgetary or regulatory changes are proposed; the resolution is a commemorative expression and call to action for awareness and research collaboration.

Background Context (as Presented in the Preamble)

• Glioblastoma is described as the most common and most aggressive malignant brain tumor with a low 5-year survival rate (7.1%) and median survival around 9 months.
• Highlights the lack of screening/early detection methods and the limited number of FDA-approved treatments specific to glioblastoma (only 5 drugs and 1 medical device since the 1920s).
• Notes the National Cancer Institute’s Glioblastoma Therapeutics Network (GTN), established in 2020, to support multi-institutional research and accelerate development of therapies.
• Underlines the high out-of-pocket costs for brain cancer patients and the urgent need for awareness and funding to advance research and treatment.

Practical Impact

• Serves as a formal congressional acknowledgment intended to:
  • Promote awareness and education about glioblastoma.
  • Honor those affected and support the communities around them.
  • Encourage continued and enhanced investment in research infrastructure and collaborative efforts to develop new treatments and improve patient outcomes.